Clinical trial · Interventional
Combined Prostate-specific Antigen, Multi-parametric MRI and Targeted Prostate Biopsy for Prostate Cancer Screening
A Clinical Study on the Efficiency of Prostate Cancer Screening by the Combination of Serum PSA Assay，Multi-parametric MRI and Targeted Prostate Biopsy Among Males in Nanjing
NCT04322045CI-TRIAL-00044276unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study aims to investigate the incidence of prostate cancer among males in Nanjing and whether a combination of PSA, multi-parametric MRI and targeted biopsy is a feasible approach for screening prostate cancer in China.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| multi-parametric MRI | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- participants
- description
- All tested serum PSA. Some conducted mpMRI with/without prostate biopsy under instruction.
- interventionNames
- Diagnostic Test: multi-parametric MRI
Primary outcomes (1)
- measure
- Incidence of prostate cancer
- timeFrame
- 3 years
- description
- Incidence of prostate cancer among males ≥50 years old
Secondary outcomes (4)
- measure
- Number of participants with different gleason scores
- timeFrame
- 3 years
- description
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 50 * (Eastern Cooperative Oncology Group)ECOG grade: 0-1 * Normal organic function indexes: * (absolute neutrophil count)ANC ≧1.5×109/L * (platelet count)PLT ≧100×109/L * Hb ≧90 g/L * (total bilirubin)TBIL ≦1.5×ULN * (aspartate aminotransferase)ALT≦2.5×ULN * (alanine aminotransferase)AST ≦2.5×ULN * (blood urea nitrogen)BUN (orUREA) and Cr ≦1.5×ULN Exclusion Criteria: * Former serum PSA detection * Having took Proscar in the past 3 months * Suffered from any other malignant tumor in the past 5 years * History of acute urinary retention, acute or chronic bacterial or abacterial prostatitis within 6 weeks or other recent infection of the urinary system * Having took Proscar in the past 3 months * Suffered from any other malignant tumor in the past 5 years * History of acute urinary retention, acute or chronic bacterial or abacterial prostatitis within 6 weeks or other recent infection of the urinary system
References
Publications (0)
Data not yet available
No reference posted for this study.